Parallax Volatility Advisers, L.P. Insmed Inc Call Options Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $6,200 - $7,901	-100 Reduced 25.0%	300 $21,000
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $173,800 - $550,709	-7,900 Reduced 95.18%	400 $26,000
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $162,036 - $188,622	6,300 Added 315.0%	8,300 $225,000
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $889,960 - $1.21 Million	-38,000 Reduced 95.0%	2,000 $61,000
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $794,400 - $1.08 Million	40,000 New	40,000 $1.01 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $296,496 - $400,582	14,200 New	14,200 $305,000
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $29,004 - $43,212	1,200 Added 6.59%	19,400 $552,000
Q1 2021 May 14, 2021	BUY	$32.28 - $44.3 $587,496 - $806,260	18,200 New	18,200 $620,000
Q2 2019 Aug 14, 2019	SELL	$23.0 - $32.19 $276,000 - $386,280	-12,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$13.91 - $31.15 $83,460 - $186,900	-6,000 Reduced 33.33%	12,000 $349,000
Q2 2018 Aug 14, 2018	BUY	$20.0 - $29.72 $360,000 - $534,960	18,000 New	18,000 $426,000

465

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.65B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.